Limits...
α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC.

Xu B, Cai Z, Zeng Y, Chen L, Du X, Huang A, Liu X, Liu J - J. Clin. Pathol. (2014)

Bottom Line: Some important clinical parameters such as α-fetoprotein, tumour numbers, dissemination to regional lymph nodes, tumour capsule and portal vein tumour thrombosis are significantly associated with the low expression of AMACR.The median survival time was 17 months in the low-expression group compared with 45 months in the high-expression group.This study reveals that the AMACR might be a potential prognostic marker for predicting early recurrence/metastasis of HCC after hepatectomy.

View Article: PubMed Central - PubMed

Affiliation: Liver Disease Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, People's Republic of China The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, People's Republic of China The Liver Center of Fujian Province, Fujian Medical University, Fuzhou, People's Republic of China.

Show MeSH

Related in: MedlinePlus

Different α-methylacyl-CoA racemase (AMACR) expression levels in hepatocellular carcinoma tumour tissues. As described in 'Methods' section, AMACR were semiquantitatively categorised into four groups: (A) negative (0), (B) weak (1+), (C) moderate (2+) and (D) strong (3+). (original magnifications 200×).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4215266&req=5

JCLINPATH2014202378F1: Different α-methylacyl-CoA racemase (AMACR) expression levels in hepatocellular carcinoma tumour tissues. As described in 'Methods' section, AMACR were semiquantitatively categorised into four groups: (A) negative (0), (B) weak (1+), (C) moderate (2+) and (D) strong (3+). (original magnifications 200×).

Mentions: To further confirm the expression profile of AMACR in patients with HCC, we constructed the TMAs and performed the IHC staining for AMACR in a large scale. After independently evaluated by two pathologists, the expression level of AMACR was scored as 0 (negative), 1 (weak), 2 (strong) or 3 (very strong). The representative images of each score are shown in figure 1. Depending on the scores, we divided the AMACR expression level into two groups: low-expression group if the final score was 0 or 1, and high-expression group if the final score was 2 or 3. Combining with the clinical history, the major factors that affect the prognosis have been collected to evaluate the relationship between the AMACR expression and the key clinical parameters.


α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC.

Xu B, Cai Z, Zeng Y, Chen L, Du X, Huang A, Liu X, Liu J - J. Clin. Pathol. (2014)

Different α-methylacyl-CoA racemase (AMACR) expression levels in hepatocellular carcinoma tumour tissues. As described in 'Methods' section, AMACR were semiquantitatively categorised into four groups: (A) negative (0), (B) weak (1+), (C) moderate (2+) and (D) strong (3+). (original magnifications 200×).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4215266&req=5

JCLINPATH2014202378F1: Different α-methylacyl-CoA racemase (AMACR) expression levels in hepatocellular carcinoma tumour tissues. As described in 'Methods' section, AMACR were semiquantitatively categorised into four groups: (A) negative (0), (B) weak (1+), (C) moderate (2+) and (D) strong (3+). (original magnifications 200×).
Mentions: To further confirm the expression profile of AMACR in patients with HCC, we constructed the TMAs and performed the IHC staining for AMACR in a large scale. After independently evaluated by two pathologists, the expression level of AMACR was scored as 0 (negative), 1 (weak), 2 (strong) or 3 (very strong). The representative images of each score are shown in figure 1. Depending on the scores, we divided the AMACR expression level into two groups: low-expression group if the final score was 0 or 1, and high-expression group if the final score was 2 or 3. Combining with the clinical history, the major factors that affect the prognosis have been collected to evaluate the relationship between the AMACR expression and the key clinical parameters.

Bottom Line: Some important clinical parameters such as α-fetoprotein, tumour numbers, dissemination to regional lymph nodes, tumour capsule and portal vein tumour thrombosis are significantly associated with the low expression of AMACR.The median survival time was 17 months in the low-expression group compared with 45 months in the high-expression group.This study reveals that the AMACR might be a potential prognostic marker for predicting early recurrence/metastasis of HCC after hepatectomy.

View Article: PubMed Central - PubMed

Affiliation: Liver Disease Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, People's Republic of China The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, People's Republic of China The Liver Center of Fujian Province, Fujian Medical University, Fuzhou, People's Republic of China.

Show MeSH
Related in: MedlinePlus